ArticleThe oncologist2019
Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase.Clinical pharmacology and therapeutics · 2025Article
- Clinical Analysis and Literature Review of 26 Patients with Hematological Malignancies During Pregnancy.Women's health reports (New Rochelle, N.Y.) · 2025Article
- Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Cancer · 2025Article
- Management of CML and Pregnancy in Low-and Middle-income Countries.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Review
- Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal transduction and targeted therapy · 2024Review
- Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution.Annals of hematology · 2023Article
- Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.Signal transduction and targeted therapy · 2023Review
- Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia.Current hematologic malignancy reports · 2023Review
- Treatment of CML in pregnancy.Hematology. American Society of Hematology. Education Program · 2022Article
- [Survey and analysis of the concerns of patients with chronic myeloid leukemia in China in 2021].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- [Diagnosis and treatment of acute leukemia during pregnancy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review.Journal of assisted reproduction and genetics · 2021Review
- Successful Planned Pregnancy through Vitrified-Warmed Embryo Transfer in a Woman with Chronic Myeloid Leukemia: Case Report and Literature Review.Mediterranean journal of hematology and infectious diseases · 2020Article
- Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations.Therapeutic advances in hematology · 2020Review
- [Fertility and disease outcomes in patients with chronic myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to explore outcomes of planned pregnancy in female patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitors (TKIs). MATERIALS AND
methodsData of female patients proceeding with a planned pregnancy were retrospectively reviewed.
resultsA total of 17 patients with CML who achieved at least a major molecular response (MMR) during imatinib (
conclusionPlanned pregnancy might be pragmatic in female patients with CML on TKIs. Achieving deep molecular response and, importantly, MMR duration ≥3.5 years were significantly associated with maintaining MMR during pregnancy. IMPLICATIONS FOR PRACTICE: Female patients with chronic myeloid leukemia on tyrosine kinase inhibitors (TKIs) wishing to conceive are currently advised to discontinue TKIs before conception. However, the ideal degree and duration of response before stopping TKI, in addition to whether there will be any adverse effect caused by a short exposure of TKI, is unknown. Data of 17 female patients, who achieved at least a major molecular response (MMR) before TKI interruption, was revised, and it was found that achieving deep molecular response and MMR duration ≥3.5 years was significantly associated with maintaining MMR during pregnancy. This provides direct evidence for a planned pregnancy strategy, and stopping TKI immediately after determination of pregnancy in female patients might be pragmatic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.